Selected research
Industry Research
Esomeprazole Industry Research Report 2026
Market perspective
The global Esomeprazole market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Esomeprazole is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Esomeprazole is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Esomeprazole is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Esomeprazole include Actavis, AstraZeneca AB, Blaskov, CQ Lummy, Garmish Pharmaceuticals, KernPharm, Mepha, Saval Pharmaceutical and Stada, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Esomeprazole market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Esomeprazole Market by Company
Actavis
AstraZeneca AB
Blaskov
CQ Lummy
Garmish Pharmaceuticals
KernPharm
Mepha
Saval Pharmaceutical
Stada
Mylan
Sanofi
Sandoz
Teva.
Esomeprazole Segment by Type
Capsule
Tablet
Others
Esomeprazole Segment by Application
Gastroesophageal Reflux Disease
Duodenal Ulcers
Others
Esomeprazole Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Esomeprazole market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Esomeprazole and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Esomeprazole.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Esomeprazole manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Esomeprazole by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Esomeprazole in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Tablet
- Others
Applications
- Gastroesophageal Reflux Disease
- Duodenal Ulcers
- Others
Companies covered
- Actavis
- AstraZeneca AB
- Blaskov
- CQ Lummy
- Garmish Pharmaceuticals
- KernPharm
- Mepha
- Saval Pharmaceutical
- Stada
- Mylan
- Sanofi
- Sandoz
- Teva.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Esomeprazole Market Size (2021-2032)
- 2.2.2 Global Esomeprazole Sales (2021-2032)
- 2.2.3 Global Esomeprazole Market Average Price (2021-2032)
- 2.3 Esomeprazole by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capsule
- 2.3.3 Tablet
- 2.3.4 Others
- 2.4 Esomeprazole by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gastroesophageal Reflux Disease
- 2.4.3 Duodenal Ulcers
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Esomeprazole Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Esomeprazole Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Esomeprazole Revenue of Manufacturers (2021-2026)
- 3.4 Global Esomeprazole Average Price by Manufacturers (2021-2026)
- 3.5 Global Esomeprazole Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Esomeprazole, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Esomeprazole, Product Type & Application
- 3.8 Global Manufacturers of Esomeprazole, Established Date
- 3.9 Global Esomeprazole Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Actavis
- 4.1.1 Actavis Company Information
- 4.1.2 Actavis Business Overview
- 4.1.3 Actavis Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Actavis Esomeprazole Product Portfolio
- 4.1.5 Actavis Recent Developments
- 4.2 AstraZeneca AB
- 4.2.1 AstraZeneca AB Company Information
- 4.2.2 AstraZeneca AB Business Overview
- 4.2.3 AstraZeneca AB Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca AB Esomeprazole Product Portfolio
- 4.2.5 AstraZeneca AB Recent Developments
- 4.3 Blaskov
- 4.3.1 Blaskov Company Information
- 4.3.2 Blaskov Business Overview
- 4.3.3 Blaskov Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Blaskov Esomeprazole Product Portfolio
- 4.3.5 Blaskov Recent Developments
- 4.4 CQ Lummy
- 4.4.1 CQ Lummy Company Information
- 4.4.2 CQ Lummy Business Overview
- 4.4.3 CQ Lummy Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CQ Lummy Esomeprazole Product Portfolio
- 4.4.5 CQ Lummy Recent Developments
- 4.5 Garmish Pharmaceuticals
- 4.5.1 Garmish Pharmaceuticals Company Information
- 4.5.2 Garmish Pharmaceuticals Business Overview
- 4.5.3 Garmish Pharmaceuticals Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Garmish Pharmaceuticals Esomeprazole Product Portfolio
- 4.5.5 Garmish Pharmaceuticals Recent Developments
- 4.6 KernPharm
- 4.6.1 KernPharm Company Information
- 4.6.2 KernPharm Business Overview
- 4.6.3 KernPharm Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 KernPharm Esomeprazole Product Portfolio
- 4.6.5 KernPharm Recent Developments
- 4.7 Mepha
- 4.7.1 Mepha Company Information
- 4.7.2 Mepha Business Overview
- 4.7.3 Mepha Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mepha Esomeprazole Product Portfolio
- 4.7.5 Mepha Recent Developments
- 4.8 Saval Pharmaceutical
- 4.8.1 Saval Pharmaceutical Company Information
- 4.8.2 Saval Pharmaceutical Business Overview
- 4.8.3 Saval Pharmaceutical Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Saval Pharmaceutical Esomeprazole Product Portfolio
- 4.8.5 Saval Pharmaceutical Recent Developments
- 4.9 Stada
- 4.9.1 Stada Company Information
- 4.9.2 Stada Business Overview
- 4.9.3 Stada Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Stada Esomeprazole Product Portfolio
- 4.9.5 Stada Recent Developments
- 4.10 Mylan
- 4.10.1 Mylan Company Information
- 4.10.2 Mylan Business Overview
- 4.10.3 Mylan Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mylan Esomeprazole Product Portfolio
- 4.10.5 Mylan Recent Developments
- 4.11 Sanofi
- 4.11.1 Sanofi Company Information
- 4.11.2 Sanofi Business Overview
- 4.11.3 Sanofi Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sanofi Esomeprazole Product Portfolio
- 4.11.5 Sanofi Recent Developments
- 4.12 Sandoz
- 4.12.1 Sandoz Company Information
- 4.12.2 Sandoz Business Overview
- 4.12.3 Sandoz Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sandoz Esomeprazole Product Portfolio
- 4.12.5 Sandoz Recent Developments
- 4.13 Teva.
- 4.13.1 Teva. Company Information
- 4.13.2 Teva. Business Overview
- 4.13.3 Teva. Esomeprazole Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Teva. Esomeprazole Product Portfolio
- 4.13.5 Teva. Recent Developments
5 Global Esomeprazole Market Scenario by Region
- 5.1 Global Esomeprazole Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Esomeprazole Sales by Region: 2021-2032
- 5.2.1 Global Esomeprazole Sales by Region: 2021-2026
- 5.2.2 Global Esomeprazole Sales by Region: 2027-2032
- 5.3 Global Esomeprazole Revenue by Region: 2021-2032
- 5.3.1 Global Esomeprazole Revenue by Region: 2021-2026
- 5.3.2 Global Esomeprazole Revenue by Region: 2027-2032
- 5.4 North America Esomeprazole Market Facts & Figures by Country
- 5.4.1 North America Esomeprazole Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Esomeprazole Sales by Country (2021-2032)
- 5.4.3 North America Esomeprazole Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Esomeprazole Market Facts & Figures by Country
- 5.5.1 Europe Esomeprazole Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Esomeprazole Sales by Country (2021-2032)
- 5.5.3 Europe Esomeprazole Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Esomeprazole Market Facts & Figures by Country
- 5.6.1 Asia Pacific Esomeprazole Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Esomeprazole Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Esomeprazole Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Esomeprazole Market Facts & Figures by Country
- 5.7.1 South America Esomeprazole Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Esomeprazole Sales by Country (2021-2032)
- 5.7.3 South America Esomeprazole Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Esomeprazole Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Esomeprazole Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Esomeprazole Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Esomeprazole Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Esomeprazole Sales by Type (2021-2032)
- 6.1.1 Global Esomeprazole Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Esomeprazole Sales Market Share by Type (2021-2032)
- 6.2 Global Esomeprazole Revenue by Type (2021-2032)
- 6.2.1 Global Esomeprazole Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Esomeprazole Revenue Market Share by Type (2021-2032)
- 6.3 Global Esomeprazole Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Esomeprazole Sales by Application (2021-2032)
- 7.1.1 Global Esomeprazole Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Esomeprazole Sales Market Share by Application (2021-2032)
- 7.2 Global Esomeprazole Revenue by Application (2021-2032)
- 7.2.1 Global Esomeprazole Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Esomeprazole Revenue Market Share by Application (2021-2032)
- 7.3 Global Esomeprazole Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Esomeprazole Value Chain Analysis
- 8.1.1 Esomeprazole Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Esomeprazole Production Mode & Process
- 8.2 Esomeprazole Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Esomeprazole Distributors
- 8.2.3 Esomeprazole Customers
9 Global Esomeprazole Analyzing Market Dynamics
- 9.1 Esomeprazole Industry Trends
- 9.2 Esomeprazole Industry Drivers
- 9.3 Esomeprazole Industry Opportunities and Challenges
- 9.4 Esomeprazole Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst